The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAhead of the upcoming second-quarter earnings release, positive expectations are mounting for major med-tech players navigating shifting market dynamics. TD Cowen has reiterated its Buy rating for Edwards Lifesciences stock, maintaining a price target of $104. The firm expects the company to meet or exceed its revenue and adjusted EPS guidance for the quarter, driven by anticipated market share gains in the transcatheter aortic valve replacement (TAVR) segment.
This optimism comes as investors monitor performance across the medical device sector, where peers like Medtronic have shown steady growth in cardiovascular segments, per market data. The $104 price target represents a significant premium over current trading levels, as analysts weigh the potential impact of upcoming catalysts, including the results from the PROGRESS clinical trial, on the company's competitive positioning.
Regarding price action, EW closed at $85.00 (close July 20, 2026), having traded within a daily range of $84.87 to $86.28. While the upcoming economic calendar shows no direct healthcare-specific events, traders are focused on the actual earnings announcement as the primary catalyst to validate the company's growth trajectory and justify the current analyst valuation.